Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Aolanti Weikang Tablets in Healthy Volunteers
NCT03358485Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Dec 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in functional dyspepsia (FD) comparing Aolanti Weikang tablets with Placebo (2 arms). Primary endpoint: Maximum-tolerated Dose at 3 weeks. Started Dec 2017; status: completed.
02
Drugs
Aolanti Weikang
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT03358485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358485.